|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 2004;77:149-150
© 2004 The Society of Thoracic Surgeons
Department of Cardiac Surgery, McGill University Health Center, 687 Pine Ave W, Suite S8.30, Montreal, Quebec, Canada H3A 1A1
e-mail: kevin.lachapelle@muhc.mcgill.ca
| The first 20% of the full text of this article appears below. |
Pulsatile ventricular assist is a recognized treatment for life threatening heart failure [1]. This type of therapy is a laborious undertaking and the complication rate following device implantation remains high, with an overall survival rate of 65% to transplant. Significant ongoing problems include bleeding, infection, right heart failure, and mechanical failure of the assist device [1, 2].
Nonpulsatile continuous flow devices have been developed and, very recently, implanted in the hope of reducing procedural complications due to their small size, ease of implantation, and easier maintenance [3, 4
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |